Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 6Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Multiple Myeloma 2Lymphoma, Follicular 2Endometrial Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Spinocerebellar Degenerations 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Malignant Solid Neoplasm 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatic Insufficiency 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

Rituximab 154Cyclophosphamide 116fludarabine phosphate 109fludarabine 68Mycophenolic Acid 62Whole-Body Irradiation 56ibrutinib 46Tacrolimus 46Peripheral Blood Stem Cell Transplantation 44Lenalidomide 43Cyclosporine 36Busulfan 35Bendamustine Hydrochloride 34Antilymphocyte Serum 31ofatumumab 30obinutuzumab 28Melphalan 28idelalisib 26Alemtuzumab 26Filgrastim 25Methotrexate 23venetoclax 22Chlorambucil 21Granulocyte Colony-Stimulating Factor 20acalabrutinib 19thymoglobulin 18Cyclosporins 16Sirolimus 15Etoposide 15Pentostatin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Lymphocytic, Chronic, B-Cell × copanlisib × Clear all
NCT04155840 2022-04-11

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

University of Washington

Phase 2 Terminated
1 enrolled 6 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡